Abstract:

Acute myelogenous leukemia(AML), a malignant blood system disease characterized by clonal proliferation and differentiation of primitive hematopoietic cells, is classified to be a heterogeneous disease, and the treatment of AML should be comprehensively considered in combination with chromosomal and molecular abnormalities, prognosis risk classification and chemotherapy tolerance of patients. Common solutions for remission induction involve DA, HA and HAD solutions, and the selection on consolidation and maintenance therapeutic regimen after remission should be considered in combination with prognosis risks of patients. Up to now, for standardized treatment of AML, Hematopoietic stem cell transplantation is still one of the most important means. The treatment of gerontal patients with AML faces more severer challenges, and targeted therapy for specific sites of leukemia cells has become the most promising therapeutic regimen, and its combination with conventional induction chemotherapy will become emerging strategy and idea for treatment of gerontal patients with AML.

Key words: leukemia,myeloid sample,acute, aged, standardized drug therapies